News & Updates
Filter by Specialty:
IBD patients at high myocarditis risk for up to 20 years
The risk of myocarditis appears to be elevated among patients with inflammatory bowel disease (IBD) for ≥20 years following diagnosis, suggests a study in Sweden. However, absolute risks remain low.
IBD patients at high myocarditis risk for up to 20 years
21 Sep 2024
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
According to patient-reported outcomes (PROs) from the TROPiCS-02 study, sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) chemotherapy is associated with health-related quality of life (HRQoL) benefits across most symptoms and functioning domains among patients with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
21 Sep 2024
Depemokimab a safe remedy for severe asthma exacerbations
Treatment with depemokimab results in a substantial decrease in exacerbations, with an acceptable safety profile, among severe asthma patients with an eosinophilic phenotype, results of the SWIFT-1 and 2 studies have shown.
Depemokimab a safe remedy for severe asthma exacerbations
20 Sep 2024
Benralizumab trumps steroids in treatment of asthma, COPD eosinophilic exacerbations
The time of steroids as the treatment of choice for asthma and chronic obstructive pulmonary disease (COPD) exacerbations appears to be nearing its end with the arrival of a new monoclonal antibody therapy, according to the results of the ABRA study.